HeartBeam shows concerning financial deterioration with interest expense surging 673% and total liabilities doubling, despite recent equity raises increasing cash position.
The massive increase in interest expense from $280K to $2.2M and doubling of total liabilities signals significant debt accumulation or unfavorable financing terms for this cash-burning medical device company. While the company raised capital (evidenced by higher cash and equity balances), the dramatic rise in financial obligations suggests potential liquidity stress or expensive bridge financing arrangements.
HeartBeam's financial profile shows mixed signals with concerning debt dynamics overshadowing capital raises. While cash increased 84% to $4.4M and stockholders' equity grew 57%, the company's total liabilities doubled to $3.2M and interest expense exploded by 673% to $2.2M, indicating expensive debt financing. R&D spending increased 22% to $13.4M and capital expenditures tripled, suggesting continued heavy investment in product development but raising questions about cash runway given the elevated interest burden and liability growth.
Interest expense surged 673.2% — significant debt increase or rising rates materially impacting earnings.
Capital expenditure jumped 198.5% — major investment cycle underway; assess returns on deployment.
Liabilities grew 99.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Cash position surged 84.3% — strong cash generation or capital raise providing significant financial cushion.
Asset base grew 78.4% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 69.1% — improving short-term liquidity or inventory/receivables build.
Equity base grew 57.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
R&D investment increased 21.7% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →